ARTICLES BY LOUIS

• Inserting The Pharmacist At The Center Of Biopharma

  The president of a college of pharmacy believes pharmacy graduates should occupy the center of the biopharma drug development and manufacturing industry. In fact, quite a few do already. More are on the way.

• Sign The “50 By 25” Declaration Of Drug Independence

  Will you become a founding signatory to the aggressive but realistic, "U.S. '50 By 25' Declaration Of Drug Independence"? And dedicate yourself to the goal of reducing dependency on foreign sources for drug materials, intermediates, substances?

• A Biopharma Life: From An Indian Village To A San-Diego Super Cluster

  A non-coronavirus-related editorial perfect for this time. Now more than ever, we recognize the value of individuals. Part 2 of our narrative with BMS's Brahmachary Enugurthi.

• When Employees Become The Supply Chain: Leadership In A Pandemic

  With your newly dispersed workforce, employees have in effect become a part of your external supply chain. How can leaders help them get through this time of uncertainty, and continue to perform at a high level? Here's some advice.

• Biopharma Answers Supply-Chain Questions Raised By COVID-19

  In terms of increasing transparency regarding the location of production, Novartis, Regeneron, GeoVac, and Gilead are positive examples for Outsourced Pharma readers.

• 3 Questions Of Risk And Communication In A Time Of Coronavirus

  Communication with your service providers may turn out most important in getting through immediate coronavirus-induced supply-chain challenges. Outsourcing may have got you into this situation; now it may be the only thing that can get you out. 

• Beck Joins Boston Pharmaceuticals: Another Sign Of The Times

  Celgene and Shire former executive Joanne Beck joins Boston Pharmaceuticals. It's another example of where drug development is heading, and how outsourcing -- and lots of funding -- are driving programs to proof-of-concept.

• Sign It, President Trump; Don’t Go There, President Xi

  If drugs are discovered as purposefully held up by China to create a supply issue in the U.S., would you ever again employ a China-based CMO? Who would have thought Outsourced Pharma readers would be front and center in presidential politics? But you are.

• U.S. Manufacturing On The Rise: Add Another CDMO To The Heartland

  Ascending U.S.-based CDMOs may exemplify a national taking back of our own supply-chain destiny. Now there’s another CDMO, Andelyn Biosciences, taking shape in Central Ohio, and targeting gene-therapy services.

• Don’t Spread The Wrong Message: COVID-19 And Respect For CMOs

  The first was to be a celebration for safely, reliably, and productively keeping drug development and manufacturing supply chains running. The second is a threat to shut those supply chains down. But here’s a second irony: This new coronavirus may have provided us an opportunity of sorts.